Pacira BioSciences, Inc.
PCRX· Nasdaq
Released May 7, 2024, after the close
10-Q filed May 7, 2024, 37 days after period end · 0001396814-24-000045
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $167.12M | $160.34M | $157.99M | $119.03M |
| Net Income | $8.98M | -$19.54M | $6.83M | $10.37M |
| EPS Diluted |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| $0.19 |
| -$0.43 |
| $0.15 |
| $0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.